Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 February 2021Next earnings report:
21 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
SABS Latest News
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.
What type of business is SAB Biotherapeutics?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
What sector is SAB Biotherapeutics in?
SAB Biotherapeutics is in the Healthcare sector
What industry is SAB Biotherapeutics in?
SAB Biotherapeutics is in the Biotechnology industry
What country is SAB Biotherapeutics from?
SAB Biotherapeutics is headquartered in United States
When did SAB Biotherapeutics go public?
SAB Biotherapeutics initial public offering (IPO) was on 09 February 2021
What is SAB Biotherapeutics website?
https://www.sabbiotherapeutics.com
Is SAB Biotherapeutics in the S&P 500?
No, SAB Biotherapeutics is not included in the S&P 500 index
Is SAB Biotherapeutics in the NASDAQ 100?
No, SAB Biotherapeutics is not included in the NASDAQ 100 index
Is SAB Biotherapeutics in the Dow Jones?
No, SAB Biotherapeutics is not included in the Dow Jones index
When does SAB Biotherapeutics report earnings?
The next expected earnings date for SAB Biotherapeutics is 21 August 2024